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Abstract
Purpose—We evaluated efficacy and tolerability of the combination of ofatumumab and 
lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), and 
explored whether immune system characteristics could influence the response to treatment.
Experimental Design—Thirty-four patients were enrolled in this phase II study. Ofatumumab 
was administered at a dose of 300 mg on day 1, 1,000 mg on days 8, 15, and 22 during course 1, 
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1,000 mg on day 1 during courses 3–6, and once every other course during courses 7–24 (28-day 
courses). Oral lenalidomide (10 mg daily) was started on day 9 and continued for as long as a 
clinical benefit was observed.
Results—The overall response rate was 71%. Eight patients (24%) achieved a complete 
remission (CR) or CR with incomplete recovery of blood counts, including 9% with minimal 
residual disease-negative CR. The median progression-free survival was 16 months, and the 
estimated 5-year survival was 53%. The most common treatment-related toxicity was neutropenia 
(grade >2 in 18% of the 574 patient courses). The most frequent infectious complications were 
pneumonia and neutropenic fever (24% and 9% of patients, respectively). We observed that 
patients who achieved a CR had at baseline higher numbers and a better preserved function of T 
cells and natural killer cells compared with non-responders.
Conclusions—The combination of ofatumumab and lenalidomide is a well-tolerated regimen 
that induces durable responses in the majority of patients with relapsed/refractory CLL. Our 
correlative data suggest a role of competent immune system in supporting the efficacy of this 
treatment.
Introduction
Chronic lymphocytic leukemia (CLL) is accompanied by a complex immune dysregulation, 
characterized by phenotypical and functional alterations of different host immune 
components. An increased number of circulating T cells in patients with CLL was observed 
for the first time more than 40 years ago (1), but the phenotypical abnormalities and 
functional defects are still under investigation (2–4). Regulatory T cells (Treg) are increased 
in patients with CLL (5). Natural killer (NK) cells are also increased and display a defective 
cytotoxic activity (6, 7).
Lenalidomide is an immunomodulatory agent that exerts both direct antitumor effect and a 
pleiotropic activity on the immune system, normalizing CD3+ T cell and Treg numbers in 
vivo (8, 9), promoting antigen-specific T cell activation, enhancing NK cell activity, and 
monocyte antibody-dependent cell cytotoxicity (ADCC; ref. 10), and restoring immunologic 
synapse formation (2).
Single-agent lenalidomide is active in patients with relapsed or refractory CLL (11, 12). In 
vitro, lenalidomide shows synergism with the anti-CD20 monoclonal antibody (mAb) 
rituximab by enhancing its CLL cell killing via NK cell- and monocyte-mediated ADCC 
(10). Our group evaluated combined rituximab and lenalidomide therapy in a phase II trial 
for patients with recurrent CLL, showing improvements in the quality and duration of 
responses when compared with lenalidomide monotherapy. Moreover, the addition of 
rituximab was accompanied by a decrease in the incidence and severity of lenalidomide-
associated tumor flare reaction (TFR) and tumor lysis syndrome (TLS; ref. 13).
Ofatumumab is a type I fully human mAb that binds to a distinct epitope on CD20 (14), and 
has clinical activity in patients with refractory CLL (15, 16).
In the current study, we determined the activity and tolerability of combined ofatumumab 
and lenalidomide for the treatment of relapsed or refractory CLL. We also conducted 
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correlative biologic studies to investigate whether immune system and tumor micro-
environment characteristics, such as circulating T- and NK cell number and function, and 
plasma levels of chemokines, cytokines, and angiogenic factors, could be correlated with the 
response to treatment or could be modulated during the course of the therapy.
Materials and Methods
Patients
Patients with relapsed or refractory CLL were enrolled in a phase II study of combined 
ofatumumab and lenalidomide. The eligibility criteria included prior exposure to purine 
analogue-based therapy. Refractory disease was defined as no response to or progression of 
disease within 6 months from the most recent antileukemia therapy (17, 18). A complete list 
of inclusion and exclusion criteria is presented in Supplementary Table S1. The study 
protocol was approved by The University of Texas MD Anderson Cancer Center 
Institutional Review Board and registered at clinicaltrials.gov (NCT01002755). Informed 
consent was obtained in accordance with institutional guidelines and the Declaration of 
Helsinki.
Treatment
Ofatumumab was administered intravenously at a dose of 300 mg on day 1, 1,000 mg on 
days 8, 15, and 22 during course 1, 1,000 mg on day 1 during courses 3–6, and on day 1 
once every other course during courses 7–24. The patients self-administered lenalidomide 10 
mg daily, orally, starting on day 9 of course 1. Each treatment course lasted 28 days. The 
planned treatment duration was 24 courses. However, patients who experienced a sustained 
partial response (PR) or complete response (CR) were allowed to continue treatment with 
lenalidomide monotherapy indefinitely. Patients were discontinued from the study if 
progression of disease or unacceptable toxicity were documented at any time. Treatment 
schema is depicted in Supplementary Fig. S1. TLS prophylaxis with allopurinol 300 mg 
daily was prescribed during the first 14 days of therapy. The use of granulocyte colony-
stimulating factor (G-CSF) was allowed according to the American Society of Clinical 
Oncology guidelines (19). No anti-infectious, venous thromboembolism (VTE), or TFR 
prophylaxis was mandated on the basis of our previous experience with lenalidomide in the 
treatment of CLL.
Response and toxicity evaluation
Response was evaluated after courses 3 and 6, then every 6 courses thereafter. The clinical 
response to therapy was defined as the best response sustained for ≥2 courses at any time 
during treatment, and assessed according to the 2008 International Workshop on CLL 
(IWCLL) criteria (17). Four-color flow cytometry was also performed on bone marrow 
aspirates to assess minimal residual disease (MRD). CT scans were not mandated for 
response assessment and were used when clinically indicated according to the treating 
physician. Patients deemed candidate for stem cell transplant were transitioned to this 
procedure according to the principle of patient's best interest. Toxicity related to the study 
drugs was assessed using Common Terminology Criteria for Adverse Events (version 3.0). 
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Treatment dose reduction plans for lenalidomide are summarized in Supplementary Table 
S2.
T and NK cell subset distribution
The absolute numbers of total (CD3+) T cells, helper (CD4+) T cells, cytotoxic (CD8+) T 
cells, Treg, CD16+CD56+ NK cells, and CD57+CD56+ NK cells were measured at baseline 
(n = 30) and at the beginning of courses 3 (n = 27), 6 (n = 21), 9 (n = 15), and 12 (n = 13), as 
described previously (8). Peripheral blood was incubated with fluorescein-conjugated mouse 
anti-human mAb to detect T-cell subsets (anti-CD3, anti-CD4, and anti-CD8), and NK cell 
subsets (anti-CD16, anti-CD56, and anti-CD57). Tregs were enumerated in peripheral blood 
mononuclear cells (PBMC) by using the Forkhead box protein P3 (FoxP3) staining kit (BD 
Pharmingen), according to the manufacturer's instructions. All reagents were purchased 
from BD Biosciences. Thirty-four age-matched healthy donors (HD) were used to establish 
normal ranges.
T cell functional assay
T cell cytotoxicity and cytokine production was assessed on 15 patients at baseline and at 
the beginning of courses 3 and 6, and on 3 HD. We preincubated PBMCs alone (negative 
control) or with CD3/CD28 magnetic beads (Invitrogen) for 6 hours at 37°C, in the presence 
of anti-CD107a-PECF594 mAb (clone H4A3, BD Biosciences) and Brefeldin A (Sigma-
Aldrich). Cells were then stained with Live/Dead Aqua Viability Marker (Life 
Technologies), and anti-CD3-BV650, anti-CD8-FITC, and anti-CD4-APC-Cy7 mAbs (BD 
Biosciences). After surface staining, cells were lysed, fixed, and permeabilized (BD FACS 
solutions, BD Biosciences). Cytokine production was detected by intracellular staining with 
anti-IFNg-v450, anti-TNFα–Alexa 700, and anti-IL2-PE mAbs (all from BD Biosciences). 
Flow cytometry data were acquired on BD LSRFortessa (BD Biosciences) and analyzed 
with FlowJo software (Treestar).
NK cell functional assay
NK cell cytotoxicity and cytokine production was assessed on 15 patients at baseline and at 
the beginning of courses 3 and 6, and on 3 HDs. PBMCs were preincubated alone (negative 
control) or with K562 target (E:T ratio of 10:1) for 5 hours at 37°C, in the presence of anti-
CD107a-PECF594 mAb, GolgiStop/monensin (BD Biosciences) and Brefeldin A. Cells 
were then stained with Live/Dead Aqua Viability Marker, anti-CD3-APC-Cy7, and anti-
CD56-BV605 mAbs (both from Biolegend). After surface staining cells were lysed, fixed, 
and permeabilized. Cytokine production was detected by intracellular staining with anti-
IFNγ-v450 and anti-TNFα- Alexa 700 mAb. Flow cytometry data were acquired on BD 
LSRFortessa and analyzed on FlowJo software.
Angiogenic factors and plasma cytokines quantification
Plasma levels of basic fibroblast growth factor (bFGF), VEGF, Thrombospondin-1, and 
IFNγ were measured at baseline (n = 32), and at the beginning of course 3 (n = 30), 6 (n = 
23), 9 (n = 17), and 12 (n = 13). Chemokine (C-C motif) ligand 2, 3, and 4 (CCL2, CCL3, 
and CCL4), TNFα, IFNα2, and IL-12p70 plasma levels were evaluated in 22 patients at 
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baseline and at the beginning of course 3. Samples were analyzed with multiplexed bead 
suspension arrays (MBAs; Millipore) according to the manufacturer's instructions and as 
described previously (12). MBAs were analyzed using a Luminex 200 machine and data 
were organized and analyzed using 3.1 xPONENT software (Luminex).
Study end points and statistical analysis
The primary endpoint of this study was the overall response rate (ORR). Differences in the 
response rates according to pretreatment characteristics were evaluated using a two-tailed 
Fisher exact test. The study's secondary objective was tolerance. Stopping rule for toxicity 
defined excessive toxicity as grade >2 nonhematologic adverse events observed in ≥50% of 
patients. Additional study objectives included the progression-free survival (PFS) duration, 
which was defined as the time from the start of therapy to death, disease progression, or 
initiation of the next therapy, and the overall survival (OS) duration, defined as time from the 
start of therapy to death from any cause. The PFS and OS durations were calculated using 
Kaplan–Meier estimates, and different groups of patients were compared using the log-rank 
test.
The modulation of T and NK cell subset distribution and function, angiogenic factors, and 
circulating cytokine/chemokine concentration between different time points was evaluated 
with paired t test, for values following Gaussian distribution, or with Wilcoxon matched-
pairs signed rank test, for values not following Gaussian distribution. The differences in 
these same parameters between CR, PR, and non-responder (NR) patients and HD were 
compared for each specific time point with t test, for values following Gaussian distribution, 
whereas Mann–Whitney test was used for values not following Gaussian distribution. 
Results were considered statistically significant when P < 0.05. Statistical analyses were 
performed using SPSS software (version 19.0; SPSS) and GraphPad Prism (version 6.05 for 
Windows, GraphPad Software).
Results
Patients
Between January 2010 and January 2011, 36 patients were enrolled in this study. Two 
patients were not evaluable: one had concomitant myelodysplastic syndrome and one 
withdrew consent before the start of treatment. The remaining 34 patients were included in 
the analyses. Patients' pretreatment characteristics are summarized in Table 1.
A median of ten courses per patient (range 2–65) was administered. All patients have 
discontinued treatment at this time. Ten patients (29%) completed the planned 24 courses of 
combination therapy,the longest treatment duration being 59 months. Reasons for treatment 
discontinuation included disease progression (18 patients, 53%), adverse events [diarrhea, 
three patients (9%); infections, four patients (12%); other adverse events, four patients 
(12%)], stem cell transplant (three patients, 9%), and patient request (two patients, 3%).
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Efficacy
Responses—Eight patients (24%) achieved CR (including 2 patients with incomplete 
recovery of blood counts, CRi) and 16 achieved PR (47%), for an ORR of 71%. Eight 
patients (24%) had stable disease (SD) and 2 (6%) experienced progression on treatment. 
The trend of response rates over time is depicted in Supplementary Fig. S2. Among the 24 
responders, median time to PR was 3 months (range 3–12 months), and median time to CR 
was 4.5 months (range 3–18 months). Three patients achieved MRD-negative CR. Among 
these patients, a clinical CR was obtained after 3, 3 and 18 months, and the time to MRD 
negativity was 12, 18, and 24 months, respectively. None of these patients were fludarabine-
refractory or had deletion of chromosome 17p (del17p).
Supplementary Table S3 shows different rates of response according to pretreatment 
characteristics. A β2-microglobulin level ≥4 mg/dL, more than three lines of prior treatment 
and fludarabine-refractoriness were associated with a lower CR rate (CRR). Fludarabine-
refractoriness was also associated with a lower ORR. Patients with del17p showed a trend 
toward a lower CRR, but this difference was only of borderline significance, possibly 
because of the small number of patients. Finally, patients receiving an average daily 
lenalidomide dose of ≥5 mg showed a trend toward superior response rates, but this was not 
statistically significant (ORR 80% vs. 61%).
PFS—The estimated median PFS duration was 16 months [95% confidence interval (CI), 
6–26 months] for the entire study population, and 25 months (95% CI, 16–34 months) for 
the 24 responders (Fig. 1A). Patients with del17p had significantly shorter PFS durations 
than those with other cytogenetic abnormalities (5 vs. 27 months, P = 0.001; Fig. 1B). 
Similarly, the estimated median PFS duration was shorter for patients with fludarabine-
refractory disease (5 vs. 28 months, P < 0.0001) and patients who had not responded to their 
last treatment before entering the study (5 vs. 22 months, P = 0.003; Fig. 1C and D). 
Interestingly, responses to ofatumumab and lenalidomide were more durable than those to 
prior therapies in 15 patients (44%). Moreover, 4 of the 10 patients who were refractory to 
their last treatment experienced long-lasting responses (15, 16, 19, and 27 months) to this 
combination (Fig. 1E). Of the three patients who achieved MRD-negative CR, two 
discontinued therapy while in remission because of toxicity after 16 and 22 months, and 
further maintained the remission for additional 13 and 14 months, respectively. The third 
patient discontinued lenalidomide after 45 months of treatment due to the wish of 
conceiving a child, and was concomitantly found to have slowly progressive disease.
OS—The median follow-up duration is 50 months (range 4–61 months) for the entire 
population. No patient died while receiving the study treatment. Seven patients died within 6 
months of treatment discontinuation, and 9 patients died at a later time. Causes of death are 
presented in Supplementary Table S4. The median OS has not been reached. The 1-year OS 
rate was 88% (95% CI: 78%–100%) and the 3-year OS rate was 65% (95% CI: 51%–83%). 
The estimated 5-year survival is 53% for all patients, and 62% for responding patients (Fig. 
2). Patients with del17p, those with fludarabine-refractoriness, and those who had undergone 
more than three lines of treatment had significantly shorter survival duration (data not 
shown).
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Safety
Overall, 574 courses of therapy were administered during the study period, with a median of 
10 courses per patient (range 2–65). The average daily dose of lenalidomide was 5.3 mg for 
the entire study cohort. It was higher in patients younger than 65 years than in those 65 years 
of age or older (6.6 mg vs. 4.1 mg, P < 0.0001). There was no correlation between the 
average daily dose of lenalidomide and serum creatinine level. Median daily dose was ≤2.5 
mg in 179 (31%), 5 mg in 226 (40%), 7.5 mg in 12 (2%), and 10 mg in 157 (27%) patient-
courses.
One patient developed a G3 infusion reaction at the time of the first dose of ofatumumab. 
Other grade 3 and 4 hematologic and nonhematologic toxicities observed during treatment 
are summarized in Table 2. We observed no grade 3 or 4 TFR or TLS. As expected, the most 
common hematologic toxicity was neutropenia, which was documented in 28 (82%) patients 
and 104 (18%) patient-courses. G-CSF was administered 37 times in 19 patients (56%). 
Treatment was temporarily interrupted due to neutropenia in 35 instances in 19 patients 
(56%).
The most frequent infectious complication was pneumonia, with 11 episodes observed in 8 
(24%) patients. Neutropenic fever occurred in 3 (9%) patients during the study period. Of 
the 24 infectious episodes observed, 16 (67%) occurred during the first 6 months of 
treatment. VTE were observed in 3 patients (9%), all with other concomitant risk factors 
(darbepoetin-α treatment and venostasis due to bulky adenopathy, raloxifene and epoetin-α 
treatment, prothrombin gene G20210A heterozygosis mutation with recurrent VTE despite 
warfarin prophylaxis).
Correlative studies
T and NK cell subset analysis—T and NK cell subset distribution was evaluated at 
baseline and during treatment with ofatumumab and lenalidomide to detect numerical 
changes and possible correlations with the response to therapy (Fig. 3). A significant 
decrease in all cell subsets during treatment was detected, and the greatest difference 
occurred at course 3 compared with baseline. When patients were categorized on the basis of 
their response to treatment (CR, n = 6; PR, n = 12; NR, n = 12), we found that patients who 
achieved a CR had higher baseline absolute numbers of CD4+ T cells and CD57+ CD56+ 
NK cells, compared with NR (median absolute number 1595/μL vs. 715/μL, P = 0.04, and 
358/μL vs. 70/μL, P = 0.02, respectively). Moreover, patients who obtained a CR had 
significantly higher baseline numbers of CD16+CD56+ and CD57+CD56+ NK cell subsets 
compared with HD (median absolute number 356/μL vs. 80/μL, P = 0.03, and 358/μL vs. 29/
μL, P = 0.0008, respectively). To evaluate the impact of the number of prior therapies on T 
and NK cell subset distribution, we compared patients who received ≤2 and >2 treatment 
regimens before lenalidomide and ofatumumab. We found a significantly lower number of 
CD56+CD57+ NK cells in patients who had received >2 treatment regimens (median 
absolute number 56/μL vs. 117/μL, P = 0.03), whereas the other T and NK cell subsets were 
not different between the two groups of patients.
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T and NK cell function—Lenalidomide, and immunomodulatory drugs in general, have 
been reported to improve T and NK cell function in vitro, including proliferation, cytokine 
production, and cytotoxicity (20–23). Here, we performed functional studies on T and NK 
cells derived from peripheral blood of 15 patients before (baseline) and at course 3 and 6 of 
ofatumumab and lenalidomide therapy. We selected 5 patients who achieved CR, 5 patients 
who achieved PR, and 5 who failed to respond to treatment. Interestingly, patients who 
achieved CR had significantly better T and NK cell function at baseline, whereas T and NK 
cell function was significantly impaired in patients who achieved only PR and NR (Fig. 4 
and Supplementary Fig. S3). During therapy, there was a gradual improvement in T cell 
function, significant only in patients who achieved CR, while NK cell function did not show 
any evidence of improvement. The number of prior treatment lines and the dose of 
lenalidomide had no significant impact on T and NK cell function.
Chemokines and cytokines—We have previously shown that during lenalidomide 
treatment patients who respond to therapy have decreased circulating levels of CCL3 and 
CCL4, compared with NR patients (24). In this series of patients, we evaluated a broader 
number of circulating chemokines/cytokines before and during treatment.
Baseline levels of CCL2, CCL3, CCL4, TNFα, IFNγ, IFNα2, and IL-12p70 were not 
significantly different in CR (n = 8), PR (n = 8), and NR (n = 6) patients (data not shown). A 
significant decrease in plasma level of IFNγ compared with baseline was observed during 
treatment, regardless of response (data not shown). During treatment, patients who achieved 
PR and CR showed significantly lower circulating levels of CCL2, CCL3, CCL4, IFNα2, 
and IL-12p70, compared with NR patients (Supplementary Fig. S4).
Angiogenic factors—No significant differences in baseline levels of bFGF, VEGF, and 
Thrombospondin-1 were found in patients grouped according to their response to treatment 
(CR: n = 8; PR: n = 12; NR: n = 12; data not shown). When compared with baseline, a 
significant decrease in patients' plasma level of bFGF and VEGF was observed during 
treatment, regardless of the response to therapy (Supplementary Fig. S5). No modulation of 
Thrombospondin-1 levels was detected (data not shown).
Discussion
Treatment regimens that are devoid of conventional cytotoxic agents are increasingly being 
developed for patients with CLL, both as initial therapy and as salvage treatment. The 
immunomodulatory properties of lenalidomide, combined with the reported activity of 
ofatumumab in patients with relapsed or refractory CLL, prompted us to evaluate the clinical 
activity of these two agents in combination and to perform correlative studies to measure the 
associated changes in T and NK cell number and function, and in circulating chemokines, 
cytokines, and angiogenic factors.
Initial studies exploring the activity of single-agent lenalidomide in relapsed or refractory 
CLL showed an ORR of 32%–47% (CR 7%–9%, PR 25%–38%; refs. 11, 12). In the current 
study, responses to treatment with ofatumumab and lenalidomide were observed in 71% of 
patients, and CR in 24%. Although comparisons between phase II studies have limitations, 
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the activity of this combination compared favorably with that of chemoimmunotherapy 
(CIT) regimens that are considered standard salvage treatments for patients with CLL. The 
fludarabine-cyclophosphamide-rituximab (FCR) regimen was given to a comparable 
population at our institution and resulted in an ORR of 73%, a CRR of 29%, and a median 
PFS duration of 19 months (25). Outcomes reported by Fischer and colleagues for relapsed 
patients treated with combined bendamustine and rituximab yielded an ORR of 59%, CRR 
of 9%, and PFS duration of 14.7 months (26). Novel treatment strategies targeting the B-cell 
receptor pathway are showing promising results, with ORR of 63% to 91% and durable 
responses based on a limited duration of follow-up (27, 28). However, low CRR and the 
observation of progression at treatment discontinuation suggest the need to investigate new 
therapeutic associations. Interestingly, the combination of lenalidomide and ibrutinib is 
being explored in the treatment of relapsed or refractory CLL (29), as well as both indolent 
and aggressive non-Hodgkin lymphoma.
In our trial, lenalidomide was given continuously until progression or development of 
unacceptable toxicity. The majority of patients (24, 70%) could not complete the planned 24 
months of treatment; however, the duration of response was heterogeneous and several long-
lasting responses (11 patients, 32%, >2 years; 6 patients, 18%, >3 years) were achieved.
We observed that the quality of responses (SD vs.PR vs. CR) can improve with time during 
therapy, and interestingly, the three patients who achieved MRD negativity did so after one 
year of therapy, confirming a different kinetic of response as compared with conventional 
CIT.
With the limitation of a relatively small patient number, we compared the efficacy of the 
combination of ofatumumab and lenalidomide with the results of our previously reported 
experience with combined rituximab and lenalidomide in patients with relapsed or refractory 
CLL (13). Baseline patient characteristics were similar between the two studies, with the 
exception of a lower median β2-microglobulin level (3.5 vs. 4.1 mg/dL) and a lower 
proportion of fludarabine-refractory cases (20% vs. 38%) among patients treated with 
rituximab and lenalidomide. The two studies had similar ORR (66% for rituximab and 
lenalidomide, and 71% for ofatumumab and lenalidomide) and response durations (17 and 
16 months, respectively). The CRR was 12% in patients treated with rituximab and 
lenalidomide and 24% in those treated with ofatumumab and lenalidomide. This difference 
could be related to a higher efficacy of ofatumumab compared with rituximab, or to other 
factors.
Achievement of an MRD-negative remission was independently correlated with longer PFS 
and OS durations in patients with CLL treated with CIT (30). Three patients treated with 
ofatumumab and lenalidomide achieved MRD-negative remission lasting 29, 36, and 45 
months, supporting a relationship between quality and duration of remission in patients 
treated with this combination.
This regimen was relatively well tolerated. We did not observe any episode of severe TLS or 
TFR, which confirms our prior observation that administering anti-CD20 mAb before 
introducing lenalidomide is an effective strategy to limit these complications. About half of 
Vitale et al. Page 9
Clin Cancer Res. Author manuscript; available in PMC 2016 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the patients experienced grade 4 neutropenia, similarly to our previous experience with 
lenalidomide in association with rituximab. Although episodes of pneumonia and fever 
appeared to be more frequent in this study (24% and 18%, respectively) compared with our 
previous study with lenalidomide and rituximab (15% and 13%, respectively), the small 
patient number limits this comparison. As the lenalidomide dose was adjusted during 
treatment according to the toxicities observed, reporting the MTD may not reflect the dose 
actually delivered for the entire treatment duration. We therefore reported the average dose 
of lenalidomide (5.3 mg). It was significantly higher in patients younger than 65 years than 
in those 65 years or older. Nevertheless, the difference in ORR between patients receiving an 
average daily lenalidomide dose of <5 mg and those receiving ≥5 mg did not reach the 
statistical significance. Our finding confirms previously published data that identified 
lenalidomide dosing for patients with CLL to be lower than that tolerated by patients with 
multiple myeloma and non-Hodgkin lymphomas.
The reported incidence of VTE in patients with CLL treated with lenalidomide-based 
regimens in the absence of thromboembolic prophylaxis is 2% to 6% (11–13, 24). In this 
study, we observed VTE in 3 patients (9%). However, these patients had concomitant risk 
factors, suggesting that, even if thromboembolic prophylaxis during lenalidomide treatment 
may not be necessary, the concomitant use of prothrombotic agents should be avoided.
We performed a series of correlative biologic studies to better understand the effects of the 
ofatumumab and lenalidomide combination on number and functional properties of T cell 
and NK cell populations, angiogenic mediators, and selected cytokines and chemokines 
known to have a role in tumor-microenvironment interactions. Moreover, we aimed to 
investigate whether some of these immune features could be correlated with response to 
treatment. Patients who achieved a CR had higher baseline numbers of T and NK cells, the 
difference being significant for CD4+T cells and CD57+CD56+ NK cells. Besides the 
number of immune cells, a better NK and T cell function at baseline appears to characterize 
patients responding to ofatumumab and lenalidomide treatment, while patients with 
dysfunctional NK and T cells had an inferior response to therapy. Although the number of 
patients evaluated is limited, our data suggest a fundamental role of the cellular immune 
system in the mechanism of action of lenalidomide and further suggest that the baseline T 
and NK cell number and function in patients with CLL may help predict their response to 
this treatment. Furthermore, our data support an important role for NK cell function in 
determining the efficiency of ofatumumab-mediated ADCC, further suggesting that better 
immune function at start of therapy is associated with a more favorable response to 
lenalidomide plus ofatumumab in CLL. Larger prospective studies are needed to determine 
if this association also applies to other therapies for CLL, and may also have future 
implications in the setting of T-cell–directed therapies.
The contribution of the tumor microenvironment in supporting CLL tumor cell survival and 
growth has been extensively studied (31). In our series, patients who responded to 
lenalidomide and ofatumumab combination had decreased circulating levels of CCL2, 
CCL3, CCL4, TNFα, IFNα2, and IL-12p70 when compared with NR. This is consistent 
with a potential effect of lenalidomide in modulating the interactions between the 
microenvironment and the CLL clone in responding patients. The observed changes are 
Vitale et al. Page 10
Clin Cancer Res. Author manuscript; available in PMC 2016 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
similar to our previous findings in patients treated with lenalidomide monotherapy (24), and 
ofatumumab does not seem to interfere with the immunomodulatory activity of 
lenalidomide.
In our patients, treatment with ofatumumab and lenalidomide induced a significant decrease 
in plasma levels of bFGF and VEGF, confirming an activity of this treatment combination in 
the disruption of proangiogenic signals (12, 32).
In conclusion, the combination of ofatumumab and lenalidomide is a feasible regimen that 
induces durable responses in the majority of patients with relapsed or refractory CLL and 
sustained MRD-negative CR in some. A higher number and preserved functional activity of 
NK and T cells were found in responding patients at baseline, as compared with NR, 
underscoring the importance of a competent immune system in supporting the effectiveness 
of this treatment and suggesting a need to further investigate these immune features as 
markers for prediction of response to therapy.
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Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
Chronic lymphocytic leukemia (CLL) is characterized by a complex dysregulation of 
both humoral and cellular immunity. Lenalidomide, an immunomodulatory agent, is an 
active treatment for CLL, exerting a direct antitumor effect, but also a pleiotropic activity 
on the immune system. Here we show that the combination of lenalidomide with the anti-
CD20 mAb ofatumumab is relatively well tolerated and can induce durable responses, 
including minimal residual disease-free complete responses (CR), in patients with 
relapsed or refractory CLL. We observed that patients who achieved a CR to treatment, 
when compared with non-responders, had higher numbers and better function of T cells 
and natural killer cells prior to treatment. These findings underscore the pivotal role, in 
terms of efficacy, played by a competent immune system at the time of treatment 
initiation, and pave the road for further studies, in an era of rapidly evolving 
immunotherapy and cell therapy approaches.
Vitale et al. Page 14
Clin Cancer Res. Author manuscript; available in PMC 2016 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Progression-free survival (PFS) and duration of response. Kaplan–Meier estimates illustrate 
PFS for all patients and for responders (A). PFS is also shown for patients categorized on the 
basis of FISH aberrations (B), fludarabine sensitivity (C), and response to the previous 
treatment (D). E, the comparison between the duration of response to the previous treatment 
and the duration of response to ofatumumab and lenalidomide therapy is shown. Each bar 
represents a patient, ordered according to the duration of response to the previous line of 
therapy.
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Figure 2. 
Overall survival (OS). Kaplan–Meier estimates illustrate OS for all patients and for 
responders.
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Figure 3. 
Number of T and NK cell subset at baseline are higher in patients achieving CR. Treatment 
with lenalidomide and ofatumumab induced a significant reduction in absolute number of 
CD3+ T cells compared with baseline levels (A, P always < 0.024), CD4+ T cells (C, P 
always < 0.021), CD8+ T cells (E, P always < 0.0046), Treg (G, P always < 0.027), 
CD16+CD56+ NK cells (I, P always < 0.0013), CD57+CD56+ NK cells (K, P always < 
0.047). Graphs represent median values and interquartile ranges for each subpopulation at 
each time point. In panels B, D, F, H, J, and L, patients are divided on the basis of response 
to treatment, and median values for each subpopulation at every time point are plotted. Gray 
shade represents the interquartile ranges for HD.
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Figure 4. 
Better NK cell and T cell function before treatment is associated with response to 
ofatumumab and lenalidomide treatment. The function of NK cells derived from CLL 
patients against K562 cells was evaluated on the basis of the expression of CD107a (A), 
IFNγ (B), and TNFα (C), at baseline and at courses 3 and 6 of treatment. NK cell effector 
function before treatment was significantly higher in patients with CR compared to patients 
with PR or NR, and was predictive of outcome. No improvement of NK cell function over 
time was seen. The function of T cells derived from CLL patients in response to CD3/CD28 
beads was evaluated on the basis of the expression of CD107a (D), IFNγ (E), TNFα (F), 
and IL2 (G) at baseline and at courses 3 and 6 of treatment. IL2 and TNFα production 
before treatment was significantly higher in CR patients compared to patients with PR or 
NR. A significant improvement in T cell function over time was seen in patients who 
achieved CR. Bars represent mean value of five patients per group ± SD.
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Table 1
Baseline patients' characteristics
Characteristic n = 34
Age, years, median (range) 64 (34–82)
Age ≥65 years, n (%) 17 (50%)
Male/female 26/8
Hemoglobin, g/dL, median (range) 12.5 (9.1–15.7)
Platelets, × 109/L, median (range) 97 (41–273)
White blood cells, × 109/L, median (range) 23.7 (2.5–125.8)
Lymphocytes, × 109/L, median (range) 19.7 (0.7–119.5)
Neutrophils, × 109/L, median (range) 2.5 (0.3–21.6)
β2-microglobulin, mg/L, median (range) 4.1 (1.7–16.5)
β2-microglobulin ≥4 mg/dL, n. (%) 20 (59%)
Rai stage, n (%)
 0–II 14 (41%)
 III–IV 20 (59%)
CD38+, n (%) 19 (56%)
CD38% expression, median (range) 32.8 (0.8–99.8)
ZAP70+, n (%)a 21 (78%)
IGHV unmutated, n (%)b 21 (70)
FISH abnormalities, n (%)c
 Deletion 13q 7 (25%)
 Negative 5 (18%)
 Trisomy 12 3 (11%)
 Deletion 11q 4 (14%)
 Deletion 17p 9 (32%)
ECOG Performance status
 0 17 (50%)
 1 17 (50%)
Number of prior treatments, median (range) 2 (1–8)
>3 prior treatments, n (%) 8 (24%)
Prior stem cell transplant, n (%) 3 (9%)
Prior FCR, n (%) 33 (97%)
Fludarabine-refractory, n (%) 13 (38%)
Refractory to previous therapy, n (%) 10 (29%)
Bulky disease, n (%) 3 (9%)
Abbreviation: FCR, fludarabine-cyclophosphamide-rituximab.
a
Data available in 27 patients.
b
Data available in 30 patients.
cGrouped according to Dohner hierarchical classification, data available in 28 patients.
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Table 2
Hematologic and non-hematologic toxicities (n = 574 patient-courses)
Grade 3 Grade 4
Toxicity Patients (%) Patient-courses (%) Patients (%) Patient-courses (%)
Hematologic
 Neutropenia 10 (29%) 75 (13%) 18 (53%) 29 (5%)
 Anemia 2 (6%) 3 (0.5%) 0 0
 Thrombocytopenia 4 (12%) 9 (1.6%) 2 (6%) 2 (0.3%)
Non-hematologic Patients (%) Episodes Patients (%) Episodes
Infections
 Pneumonia 8 (24%) 11 0 0
 Fever 3 (9%) 3 0 0
 Neutropenic fever 3 (9%) 3 0 0
 Bacteremia 1 (3%) 1 1 (3%) 1
 Cellulitis 2 (6%) 2 0 0
 Toxoplasmosis 1 (3%) 1 0 0
 Parotitis 1 (3%) 1 0 0
 Appendicitis 1 (3%) 1 0 0
Other toxicities
 VTE 2 (6%) 2 1 (3%) 1
 Dehydration 1 (3%) 1 0 0
 Fatigue 1 (3%) 1 0 0
 CHF exacerbation 1 (3%) 1 0 0
 Atrial fibrillation 1 (3%) 0 0 0
Abbreviation: CHF, congestive heart failure.
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